

Note on Biomarkers in Alzheimer's Disease

Klaus Kayser*

Department of Pathology, Charité Universitätsmedizin Berlin, Berlin, Germany

***Corresponding author:** Klaus Kayser, Department of Pathology, Charité Universitätsmedizin Berlin, Berlin, Germany, E-mail: klaus.kayser@charite.de

Received: December 0 , 2021; **Accepted:** December 20, 2021; **Published:** December 27, 2021

Copyright: © 2021 Kayser K. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

About the Study

Research in the field of Alzheimer's disease and particularly in the area of Alzheimer's disease biomarkers, continues its extraordinary growth with support from federal and nongovernmental funding

3. Rogaev EI, Sherrington R, Rogaeva EA, Levesque G, Ikeda M, et al. (1995) Familial Alzheimer's disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer's disease type 3 gene. *Nature* 376: 775-778.
4. Braak H, Braak E (1991) Neuropathological staging of Alzheimer-related changes. *Acta Neuropathol* 82: 239-259.
5. Selkoe DJ (2008) Soluble oligomers of the amyloid β -protein: Impair synaptic plasticity and behavior. *Synaptic plasticity and the mechanism of Alzheimer's disease*.
6. Terry RD, Masliah E, Salmon DP, Butters N, DeTeresa R, et al. (1991) Physical basis of cognitive alterations in Alzheimer's disease: Synapse